No evidence of benefit for universal screening with 75 g oral glucose tolerance test in polycystic ovary syndrome

Medical Journal of Australia

Volumn 195, Issue 10, 2011, Pages 578-579

  Inder, Warrick J ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; GLUCOSE; METFORMIN;

ARTICLE; BODY MASS; DIABETES MELLITUS; HEALTH CARE MANAGEMENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MASS SCREENING; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PUBLISHING; ADULT; AUSTRALIA; FEMALE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; TIME;

ADULT; AUSTRALIA; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME FACTORS; YOUNG ADULT;

EID: 84856072927     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.11307     Document Type: Article

References (13)

1. Teede HJ, Misso ML, Deeks AA, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust 2011; 195 (6 Suppl): S65-S112.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
3. Dabadghao P, Roberts BJ, Wang J, et al. Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Aust 2007; 187: 328-331.
4. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749.
5. Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome - a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92: 4546-4556.
6. Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011; 20: 37-43.
7. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968. http://whqlibdoc.who.int/php/WHO_PHP_34.pdf (accessed Oct 2011).
8. Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011; 95: 210-215.
9. Mohlig M, Floter A, Spranger J, et al. Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. Diabetologia 2006; 49: 2572-2579.
10. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
11. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
13. Franks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin Endocrinol (Oxf) 2011; 74: 148-151.